Discover our Portfolio



Theraclion, created in 2004, is a company specialized in high-tech medical equipment using therapeutic ultrasound. It designs and markets an innovative echotherapy solution: Echopulse ®. This disruptive medical device provides non-invasive, outpatient treatment for breast adenofibroma and benign thyroid nodules. Theraclion is certified ISO 13485 and has received CE marking. The company has a team of 30 people, 53% of whom are dedicated to R&D and clinical trials.

Theraclion continued growth in the 1 st half of 2018; the number of treatments has almost doubled compared to the first half of 2017, as have recurring revenues from the sale of consumables and services. Theraclion focuses on the development of the very promising indication of varicose veins, and accelerates its access to the most important markets: the countries with the strongest commercial potential in the short term and the strategic markets of the United States and China.

Theraclion focuses on the rapid launch of a varicose vein treatment solution; Theraclion completed its feasibility study and regulatory approval to allow a registration filing expected end 2018. The company is continuing its commercial efforts in Germany and neighboring countries and in Hong Kong, markets with significant commercial potential in the short term. Theraclion is making progress on access to the strategic markets of the United States and China.

The major events of 2018 include the finalization of the study on the treatment of varicose veins by echotherapy. The encouraging results obtained by Theraclion with echotherapy suggest that Theraclion has identified a relevant alternative to current solutions. Existing methods – although some are minimally invasive – have drawbacks, mainly related to the fact that they require incisions: a sterile surgical block and anesthesia (sometimes general) are mandatory. These acts are delicate to perform, a large surgical experience is required, which makes them extremely dependent on the experience of operators. Side effects such as pigmentation, inflammation, nerve damage or induration are sometimes observed. The patient who has just been treated is absolutely not autonomous and requires postoperative assistance. So many disadvantages that echoes echo therapy. This technique has the potential to respond to the shortcomings of existing methods, discover this here.

The treatment of varicose veins by echotherapy represents a gigantic market quickly accessible; the health costs of treating varicose veins are $ 9 billion a year. The venous medical device market in this budget has increased by 12% per year over the last 10 years, from approximately $ 160 million to over $ 500 million through the rapid adoption of minimally invasive methods such as than the radio frequency and the laser.

Opinion leaders in the world of phlebology have found that their patients are increasingly deciding on the alternative choices of treatments they can benefit from. A totally non-invasive solution such as echotherapy will undoubtedly be their favor. Minimally invasive techniques have paved the way for reimbursement in some markets. Many patients most often opt for a payment out of pocket to avoid invasive surgery.

Theraclion will file its application for registration simultaneously in Europe and the United States at the end of 2018. Subject to the completion of regulatory milestones, Theraclion hopes to commercialize its current solution in 2019. With a revolutionary non-invasive, precise and secure approach that meets the shortcomings of the options current, the whole project seems extremely promising.



Contact Truffle Capital

6 + 15 =

[sg_popup id=2]
5 Rue de la Baume, 75008 Paris, France Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks